Search
  1. Home
  2. Southern Africa
  3. Mozambique

GlaxoSmithKline to cut Tritanrix vaccine price

    JOHANNESBURG
    GlaxoSmithKline (GSK) said on Friday it would cut the cost of its Tritanrix HB vaccine by more than 90 percent for the Global Alliance for Vaccines and Immunisations (GAVI) for use in Mozambique. Tritanrix is a combination vaccine that provides protection against diphtheria, tetanus, and hepatitis B. Chief executive officer Jean-Pierre Garnier said: “GSK is happy to provide discount priced vaccine to Africa through GAVI. The GAVI initiative represents the kind of partnership between the public and private sector that is paramount to addressing the developing world’s healthcare needs.”

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

    We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

    Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join